Browse the evidence

Cautious use of tirzepatide is vital due to potential adverse effects and contraindications.

Healthcare providers should monitor patients closely for adverse effects when prescribing tirzepatide.

Further interventional studies involving humans are needed to better understand the role of soy isoflavones in PCOS.

More research is necessary to fully understand how soy isoflavones can be effectively used in treating PCOS.

Strategies in supporting health and performance over a player's career are encouraged.

Organizations should hire qualified nutrition professionals to support players' long-term health.

Semaglutide's success in India will depend on affordability, rational prescribing, and integration into preventive care frameworks.

Efforts should focus on making semaglutide accessible and integrating it into broader health strategies.

Further investigations are warranted regarding the effects of GLP-1-based therapies on skeletal muscle.

Practitioners should advocate for more research to better understand the implications of GLP-1 therapies on muscle health.

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) discusses 30 common obesity myths, misunderstandings, and/or oversimplifications.

Clinicians should be aware of these myths to improve patient care.

Knowledge of the underlying science may assist the obesity medicine clinician improve the care of patients with obesity.

Clinicians should leverage scientific knowledge to enhance patient outcomes.

The scientific support for this CPS is based upon published citations, clinical perspectives of OMA authors, and peer review.

The CPS is grounded in credible scientific and clinical perspectives.

Clinical inertia results in type 2 diabetes not being effectively managed.

Family physicians should be aware of the factors contributing to clinical inertia in T2D management.

Guidelines for antidiabetic drugs should provide case studies and clinical examples.

Improving guidelines with practical examples may enhance their application in clinical settings.

Clear recommendations for personalized T2D management may encourage drug prescription.

Family physicians should utilize clear recommendations to improve drug prescription practices.

Controlled metabolic accelerators (CMAs) like HU6 induce weight loss via increased mitochondrial energy expenditure (uncoupling) rather than caloric restriction, resulting in fat loss while sparing skeletal muscle mass in patients with obesity-related HFpEF.

This paper describes a new class of drugs (CMAs) that burn fat by speeding up metabolism rather than restricting food. In early studies, this approach reduced fat mass significantly while keeping muscle mass stable, unlike diet or surgery which often weaken patients. This trial tests if this works for heart failure patients with obesity. It is not a lifestyle intervention but a pharmaceutical one requiring medical supervision.

Modern obesogenic environments (sedentary lifestyle, high-calorie processed food) exploit evolutionary adaptations (brain expansion, efficient fat storage) leading to a 'normalization' of obesity phenotypes and genotypes.

Your environment is shaping your biology. To combat obesity, you must actively create a 'non-obesogenic' environment (healthy food access, physical activity) because your evolutionary biology is wired to store fat in such settings.

Ramadan Fasting (RF) protocols (28-30 days) have insufficient evidence to draw definitive conclusions regarding their effects on body weight, composition, or glycemic control compared to Time-Restricted Feeding.

Do not rely on Ramadan Fasting as a proven, standalone strategy for weight loss or metabolic health improvement based on current scientific evidence. The data is too sparse to recommend it over established methods like TRF.

High-quality studies are needed to provide definitive answers regarding the safety and duration of preoperative drug cessation for GLP-1-RAs.

Clinicians should advocate for more research to establish clear guidelines for GLP-1-RAs in the perioperative context.

There are numerous research opportunities to explore the use of metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention.

Researchers should focus on investigating the cancer prevention potential of obesity treatments.

Long-term data on the efficacy and safety of Tirzepatide are still forthcoming.

Practitioners should remain cautious and await further data on long-term outcomes before fully endorsing TZP.

Pharmacovigilance is vital in real-world settings due to the absence of sufficiently long-term studies.

Clinicians should remain vigilant about the long-term effects of AOMs in practice.

The high pricing of semaglutide (₹17,000–26,000/month) threatens equitable access.

Practitioners should be aware of the cost barriers that may limit patient access to semaglutide.

Intermittent Fasting (IMF) produces weight loss equivalent to Daily Caloric Restriction (DCR) when both interventions are delivered with comprehensive behavioral support and equal energy deficits, though IMF may offer better long-term fat mass maintenance.

This paper does not provide results, only a plan. However, it suggests that for weight loss, the specific timing of eating (fasting vs. daily restriction) matters less than sticking to the plan. If you struggle with daily calorie counting, trying fasting might work, but you need strong behavioral support (coaching, tracking) to succeed, just as you would with daily restriction.

Consuming protein immediately before resistance training may increase lower body (leg press) strength gains more than consuming it immediately after.

If you are focusing on leg strength, try eating your protein 15 minutes before your workout. This might give you a slight edge in strength gains compared to drinking it after, possibly because it provides fuel for your legs. However, this finding is based on very limited data, so don't stress if you can't make it work.

Intensive lifestyle interventions, specifically achieving significant weight loss (≥10-15 kg or ≥10% body weight), can induce Type 2 Diabetes (T2DM) remission in overweight or obese patients by correcting insulin resistance and restoring beta-cell function.

If you have Type 2 Diabetes and are overweight, losing a significant amount of weight (at least 10-15 kg) through a structured diet and exercise program can potentially put your diabetes into remission. This means your blood sugar levels may return to normal without medication. However, this requires a strong commitment to maintaining that weight loss, as the condition can return if weight is regained. Consult a doctor to see if you are a candidate, especially if your diabetes was recently diagnosed.

Lifestyle modification, specifically weight loss, dietary changes, and physical exercise, is the foundational treatment for adults with MASLD, alongside optimal management of comorbidities.

Focus on sustainable lifestyle changes: lose weight through a balanced diet and regular physical activity. Avoid alcohol. Manage other health conditions like diabetes and high blood pressure with your doctor.

Weight loss interventions (diet, multifocused weight loss, or bariatric surgery) reduce pain and disability in knee osteoarthritis, with bariatric surgery being the most effective pain-reducing intervention.

If you are overweight or obese, losing weight can significantly reduce knee pain and disability. Aim for a 5% weight loss through a combination of diet and exercise. Bariatric surgery is the most effective option for pain reduction if other methods fail.